{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:33:09Z","timestamp":1783812789566,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T00:00:00Z","timestamp":1539302400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41375-018-0278-7","type":"journal-article","created":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T13:18:25Z","timestamp":1539350305000},"page":"766-771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Preclinical assessment of an antibody\u2013PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells"],"prefix":"10.1038","volume":"33","author":[{"given":"Krista","family":"Kinneer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneetha B.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Meekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Varkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Breen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Hynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyam","family":"Bezabeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui (Tracy)","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Wetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-1646","authenticated-orcid":false,"given":"Nazzareno","family":"Dimasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Tzu","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip W.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine M.","family":"Hurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Tice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,12]]},"reference":[{"key":"278_CR1","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1200\/JCO.2007.15.8428","volume":"26","author":"CA Huff","year":"2008","unstructured":"Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol. 2008;26:2895\u2013900.","journal-title":"J Clin Oncol"},{"key":"278_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35102167","volume":"414","author":"T Reya","year":"2001","unstructured":"Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105\u201311.","journal-title":"Nature"},{"key":"278_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","volume":"24","author":"C Leung-Hagesteijn","year":"2013","unstructured":"Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24:289\u2013304.","journal-title":"Cancer Cell"},{"key":"278_CR4","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","volume":"103","author":"W Matsui","year":"2004","unstructured":"Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103:2332\u20136.","journal-title":"Blood"},{"key":"278_CR5","first-page":"3198","volume":"8","author":"LM Pilarski","year":"2002","unstructured":"Pilarski LM, Belch AR. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. Clin Cancer Res. 2002;8:3198\u2013204.","journal-title":"Clin Cancer Res"},{"key":"278_CR6","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.18632\/oncotarget.1145","volume":"4","author":"R Reghunathan","year":"2013","unstructured":"Reghunathan R, Bi C, Liu SC, Loong KT, Chung TH, Huang G, et al. Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival. Oncotarget. 2013;4:1230\u201340.","journal-title":"Oncotarget"},{"key":"278_CR7","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048\u201360.","journal-title":"Clin Cancer Res"},{"key":"278_CR8","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128\u201338.","journal-title":"Blood"},{"key":"278_CR9","doi-asserted-by":"crossref","first-page":"232546","DOI":"10.1155\/2014\/232546","volume":"2014","author":"S Mel de","year":"2014","unstructured":"de Mel S, Lim SH, Tung ML, Chng WJ. Implications of heterogeneity in multiple myeloma. Biomed Res Int. 2014;2014:232546.","journal-title":"Biomed Res Int"},{"key":"278_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/10428190500272549","volume":"47","author":"H Chang","year":"2006","unstructured":"Chang H, Samiee S, Yi QL. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leuk Lymphoma. 2006;47:43\u20137.","journal-title":"Leuk Lymphoma"},{"key":"278_CR11","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1158\/1078-0432.CCR-16-1834","volume":"23","author":"SA Kerk","year":"2017","unstructured":"Kerk SA, Finkel KA, Pearson AT, Warner KA, Zhang Z, Nor F, et al. 5T4-targeted therapy ablates cancer stem cells and prevents recurrence of head and neck squamous cell carcinoma. Clin Cancer Res. 2017;23:2516\u201327.","journal-title":"Clin Cancer Res"},{"key":"278_CR12","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1021\/acsmedchemlett.6b00062","volume":"7","author":"AC Tiberghien","year":"2016","unstructured":"Tiberghien AC, Levy JN, Masterson LA, Patel NV, Adams LR, Corbett S, et al. Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload. ACS Med Chem Lett. 2016;7:983\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"278_CR13","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1158\/1535-7163.MCT-16-0825","volume":"16","author":"J Harper","year":"2017","unstructured":"Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, et al. Preclinical evaluation of MEDI0641, a pyrrolobenzodiazepine-conjugated antibody-drug conjugate targeting 5T4. Mol Cancer Ther. 2017;16:1576\u201387.","journal-title":"Mol Cancer Ther"},{"key":"278_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158:727\u201338.","journal-title":"Br J Haematol"},{"key":"278_CR15","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","volume":"124","author":"B Barlogie","year":"2014","unstructured":"Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood. 2014;124:3043\u201351.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0278-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0278-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0278-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:35:59Z","timestamp":1684618559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-018-0278-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,12]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["278"],"URL":"https:\/\/doi.org\/10.1038\/s41375-018-0278-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,12]]},"assertion":[{"value":"6 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Y-TT declares that she has no conflict of interest. KCA is the scientific founder of Oncopep and C4 Therapeutics and serves on the advisory boards of MedImmune, Bristol-Myers Squibb, Gilead and Millenium Pharmaceuticals. PWH is an employee of Spirogen and has stock and\/or stock interests in AstraZeneca. All other authors are employees of MedImmune or were employees of MedImmune while they were involved with this work and have stock and\/or stock interests in AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}